Arbutus Biopharma’s Strategic Focus on cHBV Therapies

Photo of author
Written By Dean McHugh

Arbutus Biopharma Corporation (NASDAQ: ABUS) is at the forefront of developing therapies for chronic hepatitis B (cHBV), employing a comprehensive strategy aimed at achieving a functional cure. This strategy includes suppressing HBV DNA replication, reducing viral antigens, and enhancing immune responses through innovative drug candidates.

Leading Drug Candidate: Imdusiran (AB-729)

Credits: DepositPhotos

Imdusiran, Arbutus Biopharma’s flagship drug candidate, has demonstrated promising results in Phase 2 clinical trials. These trials have shown that Imdusiran effectively reduces HBV markers and boosts immune responses, marking a significant step forward in the pursuit of a functional cure for chronic hepatitis B.

Importantly, the drug has exhibited a favorable safety profile, further supporting its potential as a transformative treatment option.

Intellectual Property (IP) Litigation: Defending LNP Technology

Arbutus Biopharma is actively engaged in pivotal IP litigation concerning its lipid nanoparticle (LNP) delivery technology. Legal disputes with industry giants such as Moderna, Pfizer, and BioNTech could potentially result in substantial financial compensation and bolster ABUS’s IP portfolio.

A recent favorable court decision against Moderna underscores the potential for significant legal victories, which could have far-reaching implications for the company’s future.

Financial Implications of IP Wins

Successful outcomes in these litigations have the potential to significantly enhance Arbutus Biopharma’s financial position through substantial legal settlements. This could not only fortify its financial standing but also strengthen its competitive edge within the biopharmaceutical industry, potentially driving increased shareholder value.

Financial Strength and Market Position

Arbutus Biopharma maintains a robust financial position, supported by a solid cash reserve of $129.2 million in cash and short-term investments. With minimal financial debt, the company possesses ample resources to advance its clinical pipeline and vigorously defend its valuable IP assets. The market valuation of Arbutus Biopharma suggests potential undervaluation, presenting an attractive opportunity for savvy investors seeking exposure to the biotech sector.

Clinical Pipeline and Strategic Outlook

Beyond Imdusiran, Arbutus Biopharma’s clinical pipeline includes other promising candidates aimed at addressing critical unmet needs in the treatment of chronic hepatitis B. The company’s strategic focus on advancing these candidates underscores its commitment to innovation and therapeutic advancement.

Investment Outlook

Given Arbutus Biopharma’s innovative initiatives in cHBV therapies and proactive stance in defending its IP, it emerges as a standout investment opportunity within the biopharmaceutical landscape. The potential commercialization of Imdusiran and favorable legal outcomes from ongoing litigations could serve as significant catalysts for driving shareholder value.

Despite the inherent risks associated with clinical trials and IP litigation, Arbutus Biopharma’s diversified portfolio of catalysts warrants a close look from investors.

Compelling Investment In the Biopharma Sector

Credits: DepositPhotos

Arbutus Biopharma represents a compelling investment option with transformative potential in the treatment of chronic hepatitis B. Investors keen on capitalizing on cutting-edge biopharmaceutical developments and potential legal victories should consider ABUS as a value adding cornerstone of their investment portfolio.

The company’s strategic focus, strong financial footing, and promising clinical pipeline positions it favorably for long-term growth and value creation. Investors are encouraged to conduct their own research and consult with financial advisors before making investment decisions.


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.